Profiles of brain metastases: Prioritization of therapeutic targets
Open Access
- 9 October 2018
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 143 (11) , 3019-3026
Abstract
We sought to compare the tumor profiles of brain metastases from common cancers with those of primary tumors and extracranial metastases in order to identify potential targets and prioritize rational treatment strategies. Tumor samples were collected from both the primary and metastatic sites of nonsmall cell lung cancer, breast cancer and melanoma from patients in locations worldwide, and these were submitted to Caris Life Sciences for tumor multiplatform analysis, including gene sequencing (Sanger and next‐generation sequencing with a targeted 47‐gene panel), protein expression (assayed by immunohistochemistry) and gene amplification (assayed by in situ hybridization). The data analysis considered differential protein expression, gene amplification and mutations among brain metastases, extracranial metastases and primary tumors. The analyzed population included: 16,999 unmatched primary tumor and/or metastasis samples: 8,178 nonsmall cell lung cancers (5,098 primaries; 2,787 systemic metastases; 293 brain metastases), 7,064 breast cancers (3,496 primaries; 3,469 systemic metastases; 99 brain metastases) and 1,757 melanomas (660 primaries; 996 systemic metastases; 101 brain metastases). TOP2A expression was increased in brain metastases from all 3 cancers, and brain metastases overexpressed multiple proteins clustering around functions critical to DNA synthesis and repair and implicated in chemotherapy resistance, including RRM1, TS, ERCC1 and TOPO1. cMET was overexpressed in melanoma brain metastases relative to primary skin specimens. Brain metastasis patients may particularly benefit from therapeutic targeting of enzymes associated with DNA synthesis, replication and/or repair.Keywords
Funding Information
- National Institutes of Health (CA1208113, P30CA16672)
This publication has 50 references indexed in Scilit:
- EGF Receptor Activates MET through MAPK to Enhance Non–Small Cell Lung Carcinoma Invasion and Brain MetastasisCancer Research, 2013
- Survival of Patients with Non-Small-Cell Lung Cancer after a Diagnosis of Brain MetastasesCurrent Oncology, 2013
- CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primaryJournal of Cancer Research and Clinical Oncology, 2012
- The biology of brain metastases—translation to new therapiesNature Reviews Clinical Oncology, 2011
- Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarraysAnnals of Oncology, 2011
- Epidemiology of Metastatic Brain TumorsNeurosurgery Clinics of North America, 2011
- Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain MetastasisThe American Journal of Pathology, 2010
- The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC)Lung Cancer, 2010
- High expression of DNA repair pathways is associated with metastasis in melanoma patientsOncogene, 2007
- Topoisomerase IIα Expression in Breast Cancer: Correlation with Outcome VariablesLaboratory Investigation, 2000